NES
BMRN icon

New England Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

New England Securities’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,750
Closed -$109K – 1669
2014
Q2 		$109K Buy
+1,750
New +$106K 0.04% 423

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

New England Securities's BMRN Position: Q3 2014 in Review

New England Securities sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2014, closing a stake of 1,750 shares — an estimated $109K sold.

New England Securities first reported a position in BMRN in Q2 2014 and held it in 1 quarter. The position peaked at $109K in Q2 2014. 316 funds tracked by Wall St. Rank hold BMRN as of Q3 2014.

  • New England Securities reported no remaining BioMarin Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • New England Securities sold 1,750 BioMarin Pharmaceuticals shares in Q3 2014, an estimated $109K.
  • New England Securities first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • New England Securities's BioMarin Pharmaceuticals position peaked at $109K in Q2 2014.
  • 316 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2014.

Based on New England Securities's 13F filing for Q3 2014, filed 5 Nov 2014.